Oliver Weigert

Also affiliated with TUM Klinikum, LMU Klinikum, German Centre for Cardiovascular Research, Deutsches Konsortium für Translationale Krebsforschung, Ludwig-Maximilians-Universität München

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma”.

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Cancer Discovery(2020)10.1158/2159-8290.cd-19-0116

N/A

0DataRank · unranked

159 citations

Saber Tadros, Matt Teater, Lorena Fontán, Aaron Y. Chang, Neeraj Jain +24 more

Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment

Nature Communications(2024)10.1038/s41467-024-47012-1

N/A

0DataRank · unranked

29 citations

Christopher R. Chin, Hsia‐Yuan Ying, Cem Meydan, Matthew Teater, Min Xia +19 more

Identification of genetic subtypes in follicular lymphoma

Blood Cancer Journal(2024)10.1038/s41408-024-01111-w

N/A

0DataRank · unranked

13 citations

Rajesh Detroja, Ting Liu, Keren Isaev, Anjali Silva, Verena Passerini +28 more

233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)

Hematological Oncology(2025)10.1002/hon.70094_233

N/A

0DataRank · unranked

0 citations

H. Li, Heiko Schöder, Alex F. Herrera, Richard Burack, Brian K. Link +10 more